| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Arny Johannesdottir, Engilbert Sigurdsso. [The use of psilocybin for treatment-resistant depression]. Laeknabladid. vol 108. issue 9. 2022-08-30. PMID:36040772. |
the hallucinogen psilocybin is a potential novel treatment for treatment-resistant depression (trd). |
2022-08-30 |
2023-08-14 |
human |
| Caroline T Golden, Paul Chadderto. Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents. Scientific reports. vol 12. issue 1. 2022-07-26. PMID:35882885. |
psilocybin is a hallucinogenic compound that is showing promise in the ability to treat neurological conditions such as depression and post-traumatic stress disorder. |
2022-07-26 |
2023-08-14 |
mouse |
| Thomas D Meyer, Priel Meir, Claudia Lex, Jair C Soare. Magic Mushrooms - an exploratory look at how mental health professionals feel and think about Psilocybin. Psychiatry research. vol 316. 2022-07-25. PMID:35878481. |
psilocybin recently received breakthrough status by the fda for its use in treatment of depression. |
2022-07-25 |
2023-08-14 |
Not clear |
| Oliver G Bosch, Simon Halm, Erich Seifrit. Psychedelics in the treatment of unipolar and bipolar depression. International journal of bipolar disorders. vol 10. issue 1. 2022-07-05. PMID:35788817. |
first randomized, controlled trials with psilocybin show promising efficacy, tolerability, and adherence in the treatment of unipolar depression. |
2022-07-05 |
2023-08-14 |
Not clear |
| Robert Sotille, Herpreet Singh, Anne Weisman, Thomas Vid. Unraveling the Mysteries of Mental Illness With Psilocybin. Cureus. vol 14. issue 5. 2022-06-30. PMID:35769681. |
recent advancements in clinical trials using pure psilocybin in therapy suggest that it may effectively relieve the symptoms of depression in patients diagnosed with major depressive disorder and treatment-resistant depression. |
2022-06-30 |
2023-08-14 |
mouse |
| Robert Sotille, Herpreet Singh, Anne Weisman, Thomas Vid. Unraveling the Mysteries of Mental Illness With Psilocybin. Cureus. vol 14. issue 5. 2022-06-30. PMID:35769681. |
sophisticated cellular and molecular experiments at the systems level have produced evidence that demonstrates psilocybin promotes neuritogenesis in the mouse brain - a mechanism that may address the root cause of depression at the cellular level. |
2022-06-30 |
2023-08-14 |
mouse |
| Gitte M Knudse. Sustained effects of single doses of classical psychedelics in humans. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2022-06-21. PMID:35729252. |
in particular psilocybin, the psychoactive constituent in "magic mushrooms", has shown great potential for treatment of anxiety and depression. |
2022-06-21 |
2023-08-14 |
human |
| Rebecca Smausz, Joanna Neill, John Gig. Neural mechanisms underlying psilocybin's therapeutic potential - the need for preclinical in vivo electrophysiology. Journal of psychopharmacology (Oxford, England). 2022-05-31. PMID:35638159. |
answers to these questions are vital for determining the neural mechanisms mediating psilocybin's psychotherapeutic potential, which promises to improve outcomes for patients with severe depression and other difficulty to treat conditions. |
2022-05-31 |
2023-08-13 |
Not clear |
| Caroline Hayes, Mourad Wahba, Stuart Watso. Will psilocybin lose its magic in the clinical setting? Therapeutic advances in psychopharmacology. vol 12. 2022-04-28. PMID:35480296. |
psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community. |
2022-04-28 |
2023-08-13 |
Not clear |
| Roberta Murphy, Hannes Kettner, Rick Zeifman, Bruna Giribaldi, Laura Kartner, Jonny Martell, Tim Read, Ashleigh Murphy-Beiner, Michelle Baker-Jones, David Nutt, David Erritzoe, Rosalind Watts, Robin Carhart-Harri. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. Frontiers in pharmacology. vol 12. 2022-04-18. PMID:35431912. |
therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. |
2022-04-18 |
2023-08-13 |
Not clear |
| Richard E Daws, Christopher Timmermann, Bruna Giribaldi, James D Sexton, Matthew B Wall, David Erritzoe, Leor Roseman, David Nutt, Robin Carhart-Harri. Increased global integration in the brain after psilocybin therapy for depression. Nature medicine. 2022-04-12. PMID:35411074. |
increased global integration in the brain after psilocybin therapy for depression. |
2022-04-12 |
2023-08-13 |
Not clear |
| Richard E Daws, Christopher Timmermann, Bruna Giribaldi, James D Sexton, Matthew B Wall, David Erritzoe, Leor Roseman, David Nutt, Robin Carhart-Harri. Increased global integration in the brain after psilocybin therapy for depression. Nature medicine. 2022-04-12. PMID:35411074. |
we assessed the subacute impact of psilocybin on brain function in two clinical trials of depression. |
2022-04-12 |
2023-08-13 |
Not clear |
| Richard E Daws, Christopher Timmermann, Bruna Giribaldi, James D Sexton, Matthew B Wall, David Erritzoe, Leor Roseman, David Nutt, Robin Carhart-Harri. Increased global integration in the brain after psilocybin therapy for depression. Nature medicine. 2022-04-12. PMID:35411074. |
the first was an open-label trial of orally administered psilocybin (10 mg and 25 mg, 7 d apart) in patients with treatment-resistant depression. |
2022-04-12 |
2023-08-13 |
Not clear |
| Psilocybin increases brain network integration in patients with depression. Nature medicine. 2022-04-12. PMID:35411079. |
psilocybin increases brain network integration in patients with depression. |
2022-04-12 |
2023-08-13 |
Not clear |
| Mitch Earleywine, Fiona Low, Brianna R Altman, Joseph De Le. How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression? Journal of psychoactive drugs. 2022-03-23. PMID:35318904. |
how important is a guide who has taken psilocybin in psilocybin-assisted therapy for depression? |
2022-03-23 |
2023-08-13 |
human |
| Mitch Earleywine, Fiona Low, Brianna R Altman, Joseph De Le. How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression? Journal of psychoactive drugs. 2022-03-23. PMID:35318904. |
importance ratings for guides who had used psilocybin significantly exceeded the "somewhat important" level (50 on a 0-100 scale), other guide-related qualities, and comparable ratings for a cognitive behavioral therapist who shared demographics, had experience with depression and received cognitive therapy personally. |
2022-03-23 |
2023-08-13 |
human |
| Agnieszka D Sekula, Luke Downey, Prashanth Puspanatha. Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy. Frontiers in psychology. vol 13. 2022-03-21. PMID:35310225. |
psychotherapy with the use of psychedelic substances, including psilocybin, lysergic acid diethylamide (lsd), ketamine, and 3,4-methylenedioxymethamphetamine (mdma), has demonstrated promise in treatment of post-traumatic stress disorder (ptsd), anxiety, addiction, and treatment-resistant depression. |
2022-03-21 |
2023-08-13 |
human |
| Tristan D McClure-Begley, Bryan L Rot. The promises and perils of psychedelic pharmacology for psychiatry. Nature reviews. Drug discovery. 2022-03-18. PMID:35301459. |
notably, phase ii trials have shown that psilocybin can produce statistically significant clinical effects following one or two administrations in depression and anxiety. |
2022-03-18 |
2023-08-13 |
Not clear |
| Shawn Ziff, Benjamin Stern, Gregory Lewis, Maliha Majeed, Vasavi Rakesh Gorantl. Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review. Cureus. vol 14. issue 2. 2022-03-11. PMID:35273885. |
studies conducted with patients with advanced-stage cancer have demonstrated that psilocybin may also be beneficial at reducing depression and anxiety associated with psychological crises due to a terminal diagnosis. |
2022-03-11 |
2023-08-13 |
Not clear |
| Nicole Bates, Jennifer K Bello, Nosayaba Osazuwa-Peters, Mark D Sullivan, Jeffrey F Scherre. Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer. Current treatment options in oncology. 2022-03-07. PMID:35254595. |
existing evidence is inadequate to definitively recommend methylphenidate or novel agents, such as ketamine or psilocybin, as adjunctive treatments for cancer-related depression and pain. |
2022-03-07 |
2023-08-13 |
Not clear |